Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone

American Journal of Clinical Dermatology

Volumn 8, Issue 2, 2007, Pages 93-102

  Ellis, Charles N ^a   Barker, Jonathan N ^b   Haig, Ann E ^c   Parker, Christine A ^d   Daly, Susan ^d   Jayawardene, Deepthi A ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; DERMATOLOGICAL AGENT;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BODY SURFACE; CHOLECYSTITIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; THORAX PAIN; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; ADOLESCENT; HOSPITALIZATION; MIDDLE AGED; PSORIASIS;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PSORIASIS; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 34250633274     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708020-00005     Document Type: Article

References (20)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 121-8
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75
3. Feldman SR, Evans C, Russell MW. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. Dermatol Treat 2005; 16: 37-42
4. Pershadsingh HA, Sproul JA, Benjamin E, et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134: 1304-5
5. Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-16
6. Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 2005; 152: 189-91
7. Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005; 44: 328-33
8. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. Clin Endocrinol Metab 2004; 89: 2728-35
9. Venkatraman MS, Chittiboyina A, Meingassner J, et al. Alpha-lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch Dermatol Res 2004; 296: 97-104
10. Bhagavathula N, Nerusu KC, Lal A, et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122: 130-9
11. GlaxoSmithKline. Clinical trial register (292) document number CM2003/00018/00 study ID BRL-049653/292: a randomized, double-blind, placebo-controlled trial to assess three dose levels of rosiglitazone maleate (rosiglitazone) in the treatment of moderate to severe plaque psoriasis [online]. Available from URL: http://ctr.gsk.co.uk/Summary/rosiglitazone/ studylist.asp [Accessed 2006 Apr 7]
12. Langley RGB, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA), and Lattice System Physician's Global Assessment (LS-PGA). J Am Acad Dermatol 2004; 51: 563-9
13. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-3
14. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-28
15. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-66
16. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33
17. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32
18. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74
19. Schön MP. Advances in psoriasis treatment. Lancet 2005; 366: 1333-5
20. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Arch Dermatol 2001; 137: 280-4